At Fractyl, we are applying new scientific insights in intestinal biology to advance treatments and potential cures for metabolic diseases.

Our growing product pipeline leverages our minimally invasive procedural therapy, Revita™ DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. We are currently advancing global clinical development of Revita DMR, initially targeting patients with conditions resulting from insulin resistance, including type 2 diabetes (T2D), nonalcoholic steatohepatitis (NASH), and polycystic ovarian syndrome (PCOS), while also exploring use of Revita DMR in combination with cell and gene therapy.

We believe our breakthrough insights offer the potential to restore health to millions of patients worldwide and reduce the global economic burden of metabolic disease. We are steadfast in our commitment to creating solutions for all of our partners seeking new treatment options, efficient and cost-effective care, and better outcomes.

Fractyl is a privately held company headquartered in Lexington, Massachusetts.